Based on available clinical trials (INTELLECT and ALUR), local resource utilization, and unit cost data, the present economic evaluation suggests that iruplinalkib was found to be cost-effective over alectinib in treating patients with ALK-positive crizotinib-resistant advanced NSCLC in China. Here, ALK is linked to non-small cell lung carcinoma.